Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q3 2023 call → NOWe need to determine if management conveys that the company today is running on a different basis than its reported results and reputation were built on, with both halves: (1) a change of basis already real, and (2) management says the record and perception lag the change. Let's analyze the transcript. Key points from management: - Masoud Toloue: "We're pleased to announce the six-quarter transformation plan we laid out last year is expected to be substantially complete by year end, with assays rolling off our new scalable production platform in January." This indicates a transformation plan, but it's expected to be complete by year end, and assays rolling off in January. So the new basis is not fully in place yet? He says "expected to be substantially complete by year end" and "assays rolling off... in January." So the change is not yet fully realized as of the call (Q3 2023). However, he also says "Incremental improvements made throughout this year have been positively reflected in our financial results and continue to do so in the third quarter..." So some improvements are already reflected. - He says: "On the foundation of this new ops platform, we will continue to improve gross margins and take our research business from one that's burning cash to one that's generating it." That's future. - "We'll deploy capital to first expand access to our platform and second, enable patient testing with new biomarker solutions we've recently developed." That's future. - "Simoa continues to be the leader... and as we said at the beginning of this year, our goals are ubiquity." That's a goal. - "We spoke a lot this year about improving operating scale and margins. In 2024, we're going to talk a lot about increasing innovation rate..." So they are talking about future. - He mentions new agreements and tests launched: "a few weeks ago, we signed a new agreement with Johnson & Johnson Innovative Medicines and launched the Lucent AD P-tau217 blood based biomarker test..." That is a real event. But is that a change of basis? It's a new product launch, but the company has always been in diagnostics? Actually, Quanterix is a life sciences company selling instruments and consumables, and also has an Accelerator lab. The new test is a diagnostic test. But is that a fundamental change? They have been doing that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...